NAS:GBT (USA) Also Trade In: Germany UK

Global Blood Therapeutics Inc $ 40.96 0.62 (1.54%)

Volume:
1,883,921
Avg Vol (1m):
1,082,518
Market Cap $:
2.55 Bil
Enterprise Value $:
2.22 Bil
PE Ratio:
0.00
PB Ratio:
6.09
Warning! GuruFocus has detected 3 Severe warning signs with GBT. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for GBT (Global Blood Therapeutics Inc) from 2015 to Mar 06 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Global Blood Therapeutics stock (GBT) PE ratio as of Mar 06 2021 is 0. More Details

Global Blood Therapeutics PE Ratio (TTM) Chart

EMBED

Global Blood Therapeutics PE Ratio (TTM) Historical Data

Total 1245
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Global Blood Therapeutics PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2021-03-060.0 2020-12-310.0
2021-03-050.0 2020-12-300.0
2021-03-040.0 2020-12-290.0
2021-03-030.0 2020-12-280.0
2021-03-020.0 2020-12-240.0
2021-03-010.0 2020-12-230.0
2021-02-260.0 2020-12-220.0
2021-02-250.0 2020-12-210.0
2021-02-240.0 2020-12-180.0
2021-02-230.0 2020-12-170.0
2021-02-220.0 2020-12-160.0
2021-02-190.0 2020-12-150.0
2021-02-180.0 2020-12-140.0
2021-02-170.0 2020-12-110.0
2021-02-160.0 2020-12-100.0
2021-02-150.0 2020-12-090.0
2021-02-120.0 2020-12-080.0
2021-02-110.0 2020-12-070.0
2021-02-100.0 2020-12-040.0
2021-02-090.0 2020-12-030.0
2021-02-080.0 2020-12-020.0
2021-02-050.0 2020-12-010.0
2021-02-040.0 2020-11-300.0
2021-02-030.0 2020-11-270.0
2021-02-020.0 2020-11-250.0
2021-02-010.0 2020-11-240.0
2021-01-290.0 2020-11-230.0
2021-01-280.0 2020-11-200.0
2021-01-270.0 2020-11-190.0
2021-01-260.0 2020-11-180.0
2021-01-250.0 2020-11-170.0
2021-01-220.0 2020-11-160.0
2021-01-210.0 2020-11-130.0
2021-01-200.0 2020-11-120.0
2021-01-190.0 2020-11-110.0
2021-01-150.0 2020-11-100.0
2021-01-140.0 2020-11-090.0
2021-01-130.0 2020-11-060.0
2021-01-120.0 2020-11-050.0
2021-01-110.0 2020-11-040.0
2021-01-080.0 2020-11-030.0
2021-01-070.0 2020-11-020.0
2021-01-060.0 2020-10-300.0
2021-01-050.0 2020-10-290.0
2021-01-040.0 2020-10-280.0

Global Blood Therapeutics PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry Healthcare » Biotechnology » NAICS : 325411 NAICS : 2834
Traded in other countries G5B.Germany 0IVZ.UK GBT.USA
Address 171 Oyster Point Boulevard, Suite 300, South San Francisco, CA, USA, 94080
Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.